Trial Outcomes & Findings for A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) (NCT NCT04317599)
NCT ID: NCT04317599
Last Updated: 2026-01-02
Results Overview
First-line SACT treatment patterns in BRAFV600E mutant mCRC patients described by agent or combination of agents received
Recruitment status
COMPLETED
Target enrollment
274 participants
Primary outcome timeframe
time from treatment initiation (for mCRC) up to 31 December 2020
Results posted on
2026-01-02
Participant Flow
Participant milestones
| Measure |
Non Interventional
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Overall Study
STARTED
|
274
|
|
Overall Study
COMPLETED
|
255
|
|
Overall Study
NOT COMPLETED
|
19
|
Reasons for withdrawal
| Measure |
Non Interventional
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Overall Study
ineligible due to inclusion/exclusion criteria
|
15
|
|
Overall Study
treatment outside standard of care
|
4
|
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Non Interventional
n=255 Participants
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Age, Customized
≤ 60 years
|
87 Participants
n=255 Participants
|
|
Age, Customized
61-70 years
|
68 Participants
n=255 Participants
|
|
Age, Customized
> 70 years
|
100 Participants
n=255 Participants
|
|
Sex: Female, Male
Female
|
149 Participants
n=255 Participants
|
|
Sex: Female, Male
Male
|
106 Participants
n=255 Participants
|
|
Region of Enrollment
Austria
|
4 Participants
n=255 Participants
|
|
Region of Enrollment
Belgium
|
28 Participants
n=255 Participants
|
|
Region of Enrollment
Italy
|
52 Participants
n=255 Participants
|
|
Region of Enrollment
United Kingdom
|
17 Participants
n=255 Participants
|
|
Region of Enrollment
France
|
74 Participants
n=255 Participants
|
|
Region of Enrollment
Germany
|
45 Participants
n=255 Participants
|
|
Region of Enrollment
Spain
|
35 Participants
n=255 Participants
|
|
Anthropometry - Body Mass Index (BMI)
|
25.42 kg/m²
STANDARD_DEVIATION 5.44 • n=255 Participants
|
|
Disease stage at initial diagnosis
I
|
4 Participants
n=226 Participants • Data not available for all patients.
|
|
Disease stage at initial diagnosis
II
|
24 Participants
n=226 Participants • Data not available for all patients.
|
|
Disease stage at initial diagnosis
III
|
48 Participants
n=226 Participants • Data not available for all patients.
|
|
Disease stage at initial diagnosis
IV
|
150 Participants
n=226 Participants • Data not available for all patients.
|
|
Histology at initial diagnosis
Adenocarcinoma
|
252 Participants
n=253 Participants • Data not available for all patients.
|
|
Histology at initial diagnosis
Other carcinoma
|
1 Participants
n=253 Participants • Data not available for all patients.
|
|
Primary tumor location
left and/or rectum
|
83 Participants
n=255 Participants
|
|
Primary tumor location
right only
|
134 Participants
n=255 Participants
|
|
Primary tumor location
other (left and right or transverse or right and rectum or not applicable)
|
38 Participants
n=255 Participants
|
|
Number of metastatic sites
1 site
|
115 Participants
n=255 Participants
|
|
Number of metastatic sites
2 sites
|
82 Participants
n=255 Participants
|
|
Number of metastatic sites
≥3 sites
|
58 Participants
n=255 Participants
|
|
Characterization of metastasis
|
4.75 months
STANDARD_DEVIATION 12.25 • n=255 Participants
|
|
Location of metastasis
Liver
|
148 Participants
n=255 Participants
|
|
Location of metastasis
Liver only
|
48 Participants
n=255 Participants
|
|
Location of metastasis
Lungs
|
68 Participants
n=255 Participants
|
|
Location of metastasis
Lymph nodes
|
89 Participants
n=255 Participants
|
|
Location of metastasis
Bone
|
8 Participants
n=255 Participants
|
|
Location of metastasis
Peritoneum
|
112 Participants
n=255 Participants
|
|
Location of metastasis
Central Nervous System
|
2 Participants
n=255 Participants
|
|
Location of metastasis
Abdomen (including 7 patients with "ovaries")
|
12 Participants
n=255 Participants
|
|
Location of metastasis
Other
|
25 Participants
n=255 Participants
|
|
Performance Status
ECOG 0
|
80 Participants
n=150 Participants • ECOG performance status score at mCRC diagnosis was recorded for 150 patients
|
|
Performance Status
ECOG 1
|
56 Participants
n=150 Participants • ECOG performance status score at mCRC diagnosis was recorded for 150 patients
|
|
Performance Status
ECOG 2
|
10 Participants
n=150 Participants • ECOG performance status score at mCRC diagnosis was recorded for 150 patients
|
|
Performance Status
ECOG 3
|
4 Participants
n=150 Participants • ECOG performance status score at mCRC diagnosis was recorded for 150 patients
|
|
Patients with at least one comorbidity
|
129 Participants
n=253 Participants • Data not available for all patients.
|
|
Number of comorbidities
|
0.8 comorbidities
STANDARD_DEVIATION 1.0 • n=253 Participants • Data not available for all patients.
|
|
Types of comorbidity
Treated hypertension
|
100 Participants
n=253 Participants • Data not available for all patients.
|
|
Types of comorbidity
Heart rhythm disorder
|
19 Participants
n=253 Participants • Data not available for all patients.
|
|
Types of comorbidity
Peripheral vascular disease
|
15 Participants
n=253 Participants • Data not available for all patients.
|
|
Types of comorbidity
Ischemic cardiac disorder
|
12 Participants
n=253 Participants • Data not available for all patients.
|
|
Types of comorbidity
Chronic pulmonary disease
|
12 Participants
n=253 Participants • Data not available for all patients.
|
|
Types of comorbidity
Rheumatic or connective tissue disease
|
12 Participants
n=253 Participants • Data not available for all patients.
|
|
Types of comorbidity
Diabetes mellitus with end-organ damage
|
9 Participants
n=253 Participants • Data not available for all patients.
|
|
Types of comorbidity
Moderate or severe liver disease
|
6 Participants
n=253 Participants • Data not available for all patients.
|
|
Types of comorbidity
Congestive heart failure
|
4 Participants
n=253 Participants • Data not available for all patients.
|
|
Types of comorbidity
Moderate or severe renal disease
|
4 Participants
n=253 Participants • Data not available for all patients.
|
|
Types of comorbidity
Cerebrovascular disease
|
1 Participants
n=253 Participants • Data not available for all patients.
|
|
Types of comorbidity
Acquired immunodeficiency syndrome (AIDS)
|
1 Participants
n=253 Participants • Data not available for all patients.
|
|
1st line therapy received for the mCRC
monotherapy +/- Targeted Therapy (TT)
|
17 Participants
n=255 Participants
|
|
1st line therapy received for the mCRC
Doublet chemotherapy (CT)
|
72 Participants
n=255 Participants
|
|
1st line therapy received for the mCRC
Doublet CT + TT
|
118 Participants
n=255 Participants
|
|
1st line therapy received for the mCRC
Triplet CT
|
8 Participants
n=255 Participants
|
|
1st line therapy received for the mCRC
Triplet CT + TT
|
40 Participants
n=255 Participants
|
|
Number of patients with at least one surgery for either CRC or mCRC
|
163 Participants
n=255 Participants
|
|
Number of patients receiving radiotherapy for CRC or mCRC
|
29 Participants
n=255 Participants
|
|
Number of patients with at least one SACT (Systemic anti-cancer therapy) treatment
|
40 Participants
n=254 Participants • Analysis done for 254 patients
|
|
RAS testing
Mutated
|
16 Participants
n=234 Participants • 234 patients had at least one RAS testing.
|
|
RAS testing
Wild type
|
217 Participants
n=234 Participants • 234 patients had at least one RAS testing.
|
|
RAS testing
Unknown
|
1 Participants
n=234 Participants • 234 patients had at least one RAS testing.
|
|
Method of RAS testing
Next generation sequencing (NGS)
|
89 Participants
n=230 Participants • 230 patients had this information available.
|
|
Method of RAS testing
Polymerase chain reaction (PCR)
|
81 Participants
n=230 Participants • 230 patients had this information available.
|
|
Method of RAS testing
Other
|
60 Participants
n=230 Participants • 230 patients had this information available.
|
|
Microsatellite instability (MSI) testing
MSI low
|
10 Participants
n=153 Participants • 153 patients had at least one MSI testing.
|
|
Microsatellite instability (MSI) testing
MSI stable
|
103 Participants
n=153 Participants • 153 patients had at least one MSI testing.
|
|
Microsatellite instability (MSI) testing
MSI high
|
36 Participants
n=153 Participants • 153 patients had at least one MSI testing.
|
|
Microsatellite instability (MSI) testing
MSI unknown
|
4 Participants
n=153 Participants • 153 patients had at least one MSI testing.
|
|
MMR gene (if MSI was measured)
dMMR
|
29 Participants
n=119 Participants • 119 patients had this information available.
|
|
MMR gene (if MSI was measured)
pMMR
|
90 Participants
n=119 Participants • 119 patients had this information available.
|
|
Serum albumin levels
|
10.17 g/dL
STANDARD_DEVIATION 14.43 • n=96 Participants • Data not available for all patients.
|
|
Hemoglobin levels
|
11.93 g/dL
STANDARD_DEVIATION 1.91 • n=167 Participants • Data not available for all patients.
|
|
Hemoglobin levels - normal/abnormal
Abnormal
|
79 Participants
n=167 Participants • Data not available for all patients.
|
|
Hemoglobin levels - normal/abnormal
Normal (between [12 ;16] g/dL)
|
88 Participants
n=167 Participants • Data not available for all patients.
|
|
Platelet levels
|
342.64 10^9 platelets/L
STANDARD_DEVIATION 142.86 • n=166 Participants • Data not available for all patients.
|
|
Leucocyte levels
|
9.07 10^9 cells/L
STANDARD_DEVIATION 3.33 • n=165 Participants • Data not available for all patients.
|
|
Neutrophil (absolute count)
|
6.19 10^9 cells/L
STANDARD_DEVIATION 2.96 • n=151 Participants • Data not available for all patients.
|
|
Neutrophil (differential count)
|
67.75 percentage of total blood cells
STANDARD_DEVIATION 11.77 • n=145 Participants • Data not available for all patients.
|
|
C-reactive protein levels
|
13.99 mg/L
STANDARD_DEVIATION 12.45 • n=61 Participants • This data was not available for all patients.
|
|
Carcinoembryonic antigen (CEA) levels
|
16.20 ng/mL
STANDARD_DEVIATION 18.46 • n=109 Participants • This data was not available for all patients.
|
|
Carbohydrate antigen 19-9 (CA 19.9) levels
|
149.18 U/mL
STANDARD_DEVIATION 220.75 • n=79 Participants • This data was not available for all patients.
|
PRIMARY outcome
Timeframe: time from treatment initiation (for mCRC) up to 31 December 2020Population: \*treated as doublet CT + anti-EGFR for analysis.
First-line SACT treatment patterns in BRAFV600E mutant mCRC patients described by agent or combination of agents received
Outcome measures
| Measure |
Non Interventional
n=255 Participants
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT + TT : Doublet CT + anti-VEGF : FOLFIRI / Aflibercept
|
2 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT + TT : Doublet CT + anti-VEGF : FOLFIRI / Bevacizumab
|
20 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT + TT : Doublet CT + anti-VEGF : FOLFOX / Bevacizumab
|
69 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT + TT : Doublet CT + anti-EGFR
|
19 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT + TT : Doublet CT + anti-EGFR : FOLFIRI / Cetuximab
|
3 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT + TT : Doublet CT + anti-EGFR : FOLFIRI / Panitumumab
|
2 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT + TT : Doublet CT + anti-EGFR : Tomiri / Panitumumab
|
1 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT + TT : Doublet CT + anti-EGFR : FOLFOX / Cetuximab
|
5 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT + TT : Doublet CT + anti-EGFR : FOLFOX / Panitumumab
|
7 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT + TT : Doublet CT + anti-EGFR : FOLFOX / Cetuximab + Avelumab*
|
1 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Triplet CT
|
8 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Triplet CT : : FOLFIRINOX
|
2 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Triplet CT : : FOLFOXIRI
|
6 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Triplet CT + TT
|
40 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Triplet CT + TT : Triplet + anti-VEGF
|
38 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Triplet CT + TT : Triplet + anti-VEGF : FOLFIRINOX / Bevacizumab
|
4 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Triplet CT + TT : Triplet + anti-VEGF : FOLFOXIRI / Bevacizumab
|
34 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Triplet CT + TT : Triplet + anti-EGFR
|
2 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Triplet CT + TT : Triplet + anti-EGFR : FOLFOXIRI / Cetuximab
|
1 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Triplet CT + TT : Triplet + anti-EGFR : FOLFOXIRI / Panitumumab
|
1 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet chemotherapy (CT)
|
72 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Monotherapy +/- targetted therapy (TT)
|
17 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Monotherapy +/- TT : : Fluropyrimidine monotherapy
|
6 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Monotherapy +/- TT : : Fluropyrimidine monotherapy / Bevacizumab
|
10 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Monotherapy +/- TT : : Fluropyrimidine monotherapy / Panitumumab
|
1 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT : : CAPOX
|
11 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT : : FOLFIRI
|
7 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT : : FOLFOX
|
49 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT : : Fluoropyrimidine + (Irinotecan or Folic Acid)
|
3 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT : : XELIRI
|
2 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT + TT
|
118 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT + TT : Doublet CT + anti-VEGF
|
99 Participants
|
|
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
Doublet CT + TT : Doublet CT + anti-VEGF : CAPOX / Bevacizumab
|
8 Participants
|
PRIMARY outcome
Timeframe: time from treatment initiation (for mCRC) up to 31 December 2020Population: A total of 255 patients were included in the full analysis set (FAS). Data for 2 patients were not available.
First-line SACT treatment patterns in BRAFV600E mutant mCRC patients described by Duration of Treatment
Outcome measures
| Measure |
Non Interventional
n=253 Participants
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Duration of Treatment for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
|
6.04 months
Standard Deviation 5.79
|
PRIMARY outcome
Timeframe: time from treatment initiation (for mCRC) up to 31 December 2020Switch in mCRC first-line SACT treatment in BRAFV600E mutant mCRC patients.
Outcome measures
| Measure |
Non Interventional
n=255 Participants
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Reason for switch: toxicity
|
24 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Reason for switch: lack of response
|
13 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Reason for switch: other
|
13 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch to: FOLFOX
|
21 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch to: CAPOX
|
1 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch to: FOLFIRI
|
16 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch to: Fluoropyrimidine monotherapy
|
27 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch to: FOLFOXIRI
|
4 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch to: FOLFIRINOX
|
3 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch to: BRAFi + Other
|
1 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
If switch with FOLFOX, CAPOX, FOLFIRI, Fluoropyrimidine or FOLFIXIRI -
|
53 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
- then, in combination with: Panitumumab
|
4 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
- then, in combination with: Cetuximab
|
1 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
- then, in combination with: Bevacizumab
|
48 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: CAPOX / Bevacizumab
|
1 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: FOLFIRI
|
6 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: FOLFIRI / Bevacizumab
|
8 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: FOLFIRI / Cetuximab
|
1 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: FOLFIRI / Panitumumab
|
1 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: FOLFIRINOX
|
2 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: FOLFIRINOX / Bevacizumab
|
1 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: FOLFOX
|
6 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: FOLFOX / Bevacizumab
|
14 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: FOLFOX / Panitumumab
|
1 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: FOLFOXIRI / Bevacizumab
|
4 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: Tomiri
|
1 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch to other treatment
|
80 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch to other treatment: maintenance
|
30 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch to: Tomiri
|
1 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch to: Fluoropyrimidine + (Leucovorin or Folinic Acid)
|
2 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch to: Other
|
4 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: BRAFi + Other
|
1 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: Fluoropyrimidine monotherapy
|
6 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: Fluoropyrimidine monotherapy / Bevacizumab
|
19 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: Fluoropyrimidine monotherapy / Panitumumab
|
2 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: Fluoropyrimidine + (Leucovorin or Folinic Acid)
|
1 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: Fluoropyrimidine + (Leucovorin or Folinic Acid) / Bevacizumab
|
1 Participants
|
|
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch regiment: Other
|
4 Participants
|
SECONDARY outcome
Timeframe: from the date of the start of first-line treatment for mCRC up to 31 December 2020Population: Disease stage at initial diagnosis of CRC by first line treatment regimen Data were available for 226 of the 255 patients included in the FAS
Description of the demographic and clinical profile of patients at the time of treatment initiation (for mCRC) TNM stage of colorectal cancer. Stage I: Cancer is still in the inner lining, but has grown through the mucosa of the colon and invaded the muscle layer. Stage II: The cancer has grown beyond the mucosa of the colon but has not spread to the lymph nodes Stage III: The cancer has spread to the lymph nodes near the colon, it has not spread further. Stage IV: The cancer has spread outside of the colon and has been carried through the lymph and blood systems to distant parts of the body, this is known as metastasis.
Outcome measures
| Measure |
Non Interventional
n=226 Participants
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Demographic and Clinical Characteristics
Doublet CT · TNM Stage IV
|
41 Participants
|
|
Demographic and Clinical Characteristics
Triplet CT · TNM Stage I
|
0 Participants
|
|
Demographic and Clinical Characteristics
Monotherapy +/- TT · TNM Stage I
|
0 Participants
|
|
Demographic and Clinical Characteristics
Monotherapy +/- TT · TNM Stage II
|
3 Participants
|
|
Demographic and Clinical Characteristics
Monotherapy +/- TT · TNM Stage III
|
4 Participants
|
|
Demographic and Clinical Characteristics
Monotherapy +/- TT · TNM Stage IV
|
8 Participants
|
|
Demographic and Clinical Characteristics
Doublet CT · TNM Stage I
|
1 Participants
|
|
Demographic and Clinical Characteristics
Doublet CT · TNM Stage II
|
7 Participants
|
|
Demographic and Clinical Characteristics
Doublet CT · TNM Stage III
|
10 Participants
|
|
Demographic and Clinical Characteristics
Doublet CT + TT · TNM Stage I
|
2 Participants
|
|
Demographic and Clinical Characteristics
Doublet CT + TT · TNM Stage II
|
10 Participants
|
|
Demographic and Clinical Characteristics
Doublet CT + TT · TNM Stage III
|
26 Participants
|
|
Demographic and Clinical Characteristics
Doublet CT + TT · TNM Stage IV
|
75 Participants
|
|
Demographic and Clinical Characteristics
Triplet CT · TNM Stage III
|
2 Participants
|
|
Demographic and Clinical Characteristics
Triplet CT · TNM Stage IV
|
4 Participants
|
|
Demographic and Clinical Characteristics
Triplet CT + TT · TNM Stage I
|
1 Participants
|
|
Demographic and Clinical Characteristics
Triplet CT + TT · TNM Stage II
|
4 Participants
|
|
Demographic and Clinical Characteristics
Triplet CT + TT · TNM Stage III
|
6 Participants
|
|
Demographic and Clinical Characteristics
Triplet CT + TT · TNM Stage IV
|
22 Participants
|
|
Demographic and Clinical Characteristics
Triplet CT · TNM Stage II
|
0 Participants
|
SECONDARY outcome
Timeframe: from the date of the start of first-line treatment for mCRC up to 31 December 2020the length of time between initiation of first-line treatment for mCRC and the first documented disease progression or death. Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Outcome measures
| Measure |
Non Interventional
n=255 Participants
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Progression-free Survival (PFS)
|
5.98 months
Interval 5.32 to 6.67
|
SECONDARY outcome
Timeframe: from the date of the start of first-line treatment for mCRC up to 31 December 2020length of time between first-line treatment initiation (for mCRC) and death (due to any cause)
Outcome measures
| Measure |
Non Interventional
n=255 Participants
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Overall Survival (OS)
|
12.68 months
Interval 11.6 to 14.13
|
SECONDARY outcome
Timeframe: from the date of the start of first-line treatment for mCRC until the end of first-line treatment up to 31 December 2020Population: Data were available for 221 of the 255 patients included in the FAS
complete response (CR) or partial response (PR), during the first line treatment Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Outcome measures
| Measure |
Non Interventional
n=221 Participants
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Overall Response Rate (ORR)
|
37.1 percentage of participants
Interval 30.7 to 43.5
|
SECONDARY outcome
Timeframe: from the date of the start of first-line treatment for mCRC until the documented disease progression up to 31 December 2020the length of time between initiation of first-line treatment for mCRC and documented disease progression (or start of subsequent Line Of Treatment (LOT), if disease progression is not well documented in patient medical record), treatment discontinuation or switch to another treatment (defined as change from one treatment regimen to another treatment regimen, e.g., change from FOLFOX-based regimen to FOLFIRI or irinotecan-based regimen)
Outcome measures
| Measure |
Non Interventional
n=255 Participants
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Time to Treatment Cessation
|
4.83 months
Interval 4.01 to 5.32
|
SECONDARY outcome
Timeframe: from the date of the start of first-line treatment for mCRC until the end of first-line treatment up to 31 December 2020Population: Data not available for all patients.
Description of testing procedures of BRAF mutation testing since mCRC diagnosis and since first-line treatment for mCRC
Outcome measures
| Measure |
Non Interventional
n=255 Participants
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
If tumor sample, tumor sample tested: archival
|
175 Participants
|
|
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
If tumor sample, tumor sample tested: fresh
|
53 Participants
|
|
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
Method used: PCR
|
104 Participants
|
|
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
Method used: NGS
|
86 Participants
|
|
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
Method used: Other
|
10 Participants
|
|
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
Method used: high resolution melting
|
4 Participants
|
|
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
Method used: mass spectrometry
|
22 Participants
|
|
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
Number of BRAF testing: 1
|
244 Participants
|
|
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
Number of BRAF testing: 2
|
11 Participants
|
|
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
Timing of 1st BRAF testing: before 1L (2 to 38 months before 1st line initiation)
|
62 Participants
|
|
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
Timing of 1st BRAF testing: before 1L (less than 2 months before 1st line initiation)
|
140 Participants
|
|
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
Timing of 1st BRAF testing: during 1L
|
21 Participants
|
|
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
Timing of 1st BRAF testing: after 1L and before 2L
|
1 Participants
|
|
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
Timing of 1st BRAF testing: during 2L
|
1 Participants
|
|
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
BRAF test sample: tumor sample
|
252 Participants
|
|
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
BRAF test sample: ctDNA
|
3 Participants
|
SECONDARY outcome
Timeframe: from the date of the start of first-line treatment for mCRC until the end of first-line treatment up to 31 December 2020Population: Data not available for all patients.
Time to BRAF mutation testing since mCRC diagnosis and since first-line treatment for mCRC
Outcome measures
| Measure |
Non Interventional
n=255 Participants
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Description of BRAF Mutation Testing Timing in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
Time from metastatic diagnosis to 1st BRAF mutation testing (if after metastatic diagnosis)
|
0.6 months
Standard Error 1.7
|
|
Description of BRAF Mutation Testing Timing in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
Time from metastatic diagnosis to 1st BRAF mutation testing (if before metastatic diagnosis)
|
6.1 months
Standard Error 7.9
|
OTHER_PRE_SPECIFIED outcome
Timeframe: from the date of the start of first-line treatment for mCRC until the end of first-line treatment up to 31 December 2020Population: \*due to other reasons than progression or toxicity.
Description of reasons for alteration or discontinuation of first-line treatment for mCRC in BRAFV600E Mutant mCRC Patients
Outcome measures
| Measure |
Non Interventional
n=255 Participants
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients
Patient with treatment alteration
|
137 Participants
|
|
Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients
Most important reason for treatment alteration: Planned alteration
|
10 Participants
|
|
Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients
Most important reason for treatment alteration: Toxicity
|
100 Participants
|
|
Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients
Most important reason for treatment alteration: Poor performance status of patient
|
6 Participants
|
|
Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients
Most important reason for treatment alteration: Other
|
16 Participants
|
|
Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients
Patient with treatment discontinuation
|
248 Participants
|
|
Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients
Most important reason for treatment discontinuation: Progression
|
158 Participants
|
|
Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients
Most important reason for treatment discontinuation: Toxicity
|
19 Participants
|
|
Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients
Most important reason for treatment discontinuation: BRAF test available
|
5 Participants
|
|
Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients
Most important reason for treatment discontinuation: Planned discontinuation
|
21 Participants
|
|
Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients
Most important reason for treatment discontinuation: Patient choice
|
6 Participants
|
|
Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients
Most important reason for treatment discontinuation: Poor performance status of patient
|
16 Participants
|
|
Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients
Most important reason for treatment discontinuation: Death*
|
4 Participants
|
|
Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients
Most important reason for treatment discontinuation: Other
|
9 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: from the date of the start of first-line treatment for mCRC until the end of first-line treatment up to 31 December 2020Population: Not all patients went through all lines of treatment.
Description of the types of treatments after first-line SACT treatment (2nd-line to 7th-line) in BRAFV600E Mutant mCRC Patients.
Outcome measures
| Measure |
Non Interventional
n=255 Participants
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · BRAFi / Cetuximab
|
7 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · BRAFi / Cetuximab + Irinotecan
|
4 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · BRAFi / MEKi / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · CAPOX
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · Cetuximab monotherapy
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · FOLFIRI
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · FOLFIRI / Aflibercept
|
4 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · FOLFIRI / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · FOLFIRI / Cetuximab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · FOLFIRI / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · FOLFOX
|
4 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · FOLFOX / Bevacizumab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · FOLFOX / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · FOLFOX / Panitumumab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · FOLFOXIRI
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · BRAFi+ Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · BRAFi / MEKi / Cetuximab
|
16 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · BRAFi / MEKi / Panitumumab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · CAPOX
|
2 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · Cetuximab monotherapy
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · FOLFIRI
|
19 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · FOLFIRI / Aflibercept
|
7 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · FOLFIRI / Bevacizumab
|
20 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · FOLFIRI / Cetuximab
|
8 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · FOLFIRI / Panitumumab
|
5 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · FOLFOX
|
4 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · FOLFIRI / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · FOLFOX
|
2 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · FOLFOX / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · FOLFOX / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · FOLFOX / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · FOLFOXIRI
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · FOLFOX / Bevacizumab
|
7 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · FOLFOX / Cetuximab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · FOLFOX / Panitumumab
|
3 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · FOLFOXIRI
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · FOLFOXIRI / Bevacizumab
|
6 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · Fluoropyrimidine monotherapy
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · Fluoropyrimidine monotherapy / Bevacizumab
|
2 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · Fluoropyrimidine + (Leucovorin or Folinic Acid)
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · FOLFOXIRI / Bevacizumab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · Irinotecan
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · Irinotecan / Cetuximab
|
4 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · Irinotecan / Panitumumab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · Other
|
7 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · Panitumumab monotherapy
|
2 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · XELIRI / Bevacizumab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · BRAFi
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · Fluoropyrimidine monotherapy / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · Fluoropyrimidine + (Leucovorin or Folinic Acid) / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · BRAFi / Cetuximab
|
2 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · BRAFi / Cetuximab + Irinotecan
|
5 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · Fluoropyrimidine monotherapy
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · Fluoropyrimidine monotherapy / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · Fluoropyrimidine + (Leucovorin or Folinic Acid)
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · BRAFi+ Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · BRAFi / MEKi / Cetuximab
|
6 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · BRAFi / MEKi / Panitumumab
|
2 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · CAPOX
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · Cetuximab monotherapy
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · FOLFIRI
|
2 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · FOLFIRI / Aflibercept
|
4 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · FOLFIRI / Bevacizumab
|
9 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · FOLFIRI / Cetuximab
|
2 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · FOLFIRI / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · FOLFOX
|
4 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · FOLFOX / Bevacizumab
|
5 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · FOLFOX / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · FOLFOX / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · FOLFOXIRI
|
2 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · FOLFOXIRI / Bevacizumab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · Fluoropyrimidine monotherapy
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · Fluoropyrimidine monotherapy / Bevacizumab
|
3 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · Fluoropyrimidine + (Leucovorin or Folinic Acid)
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · Irinotecan
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · Irinotecan / Cetuximab
|
2 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · Irinotecan / Panitumumab
|
2 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · Other
|
20 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · Panitumumab monotherapy
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · XELIRI / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · BRAFi
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · CAPOX / Bevacizumab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · Fluoropyrimidine monotherapy / Panitumumab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
3rd · Fluoropyrimidine + (Leucovorin or Folinic Acid) / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · BRAFi / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · BRAFi / Cetuximab + Irinotecan
|
2 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · BRAFi+ Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · BRAFi / MEKi / Cetuximab
|
3 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · BRAFi+ Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · BRAFi / MEKi / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · BRAFi / MEKi / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · CAPOX
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · Cetuximab monotherapy
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · FOLFIRI
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · FOLFIRI / Aflibercept
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · FOLFIRI / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · FOLFIRI / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · FOLFIRI / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · FOLFOX
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · FOLFOX / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · FOLFOX / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · FOLFOX / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · FOLFOXIRI
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · FOLFOXIRI / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · Fluoropyrimidine monotherapy
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · Fluoropyrimidine monotherapy / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · Fluoropyrimidine + (Leucovorin or Folinic Acid)
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · Irinotecan
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · Irinotecan / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · Irinotecan / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · Other
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · Panitumumab monotherapy
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · XELIRI / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · BRAFi
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · CAPOX / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · Fluoropyrimidine monotherapy / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · Fluoropyrimidine + (Leucovorin or Folinic Acid) / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · Irinotecan
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · Irinotecan / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · Other
|
15 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · Panitumumab monotherapy
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · XELIRI / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · BRAFi
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · CAPOX / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · Fluoropyrimidine + (Leucovorin or Folinic Acid) / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · BRAFi / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · BRAFi / Cetuximab + Irinotecan
|
2 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · BRAFi+ Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · BRAFi / MEKi / Cetuximab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · BRAFi / MEKi / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · CAPOX
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · Cetuximab monotherapy
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · FOLFIRI / Aflibercept
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · FOLFIRI / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · FOLFIRI / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · FOLFIRI / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · FOLFOX
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · FOLFOX / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · FOLFOX / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · FOLFOX / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · FOLFOXIRI
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · FOLFOXIRI / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · Fluoropyrimidine monotherapy
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · Fluoropyrimidine monotherapy / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · Fluoropyrimidine + (Leucovorin or Folinic Acid)
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · Irinotecan
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · Irinotecan / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · Irinotecan / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · FOLFOXIRI / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · Fluoropyrimidine monotherapy
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · Fluoropyrimidine monotherapy / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · Fluoropyrimidine + (Leucovorin or Folinic Acid)
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · Irinotecan
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · Irinotecan / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · Irinotecan / Panitumumab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · Other
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · Panitumumab monotherapy
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · XELIRI / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · Fluoropyrimidine monotherapy / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · Fluoropyrimidine + (Leucovorin or Folinic Acid) / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · BRAFi / Cetuximab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
7th line · BRAFi / Cetuximab + Irinotecan
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
2nd · CAPOX / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · Irinotecan / Cetuximab
|
2 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
4th line · Fluoropyrimidine monotherapy / Panitumumab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · FOLFIRI
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · Other
|
8 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · Panitumumab monotherapy
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · CAPOX / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · Fluoropyrimidine monotherapy / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · CAPOX
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · FOLFIRI / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · BRAFi
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · CAPOX / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · XELIRI / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · BRAFi
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · FOLFIRI / Bevacizumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
5th line · Fluoropyrimidine + (Leucovorin or Folinic Acid) / Bevacizumab
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · BRAFi / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · BRAFi / Cetuximab + Irinotecan
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · BRAFi+ Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · BRAFi / MEKi / Cetuximab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · BRAFi / MEKi / Panitumumab
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · Cetuximab monotherapy
|
1 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · FOLFIRI
|
0 Participants
|
|
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
6th line · FOLFIRI / Aflibercept
|
0 Participants
|
Adverse Events
Non Interventional
Serious events: 40 serious events
Other events: 104 other events
Deaths: 206 deaths
Serious adverse events
| Measure |
Non Interventional
n=255 participants at risk
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Blood and lymphatic system disorders
Blood and lymphatic system disorders
|
2.7%
7/255 • Number of events 9 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Cardiac disorders
Cardiac disorders
|
0.78%
2/255 • Number of events 2 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Gastrointestinal disorders
Gastrointestinal disorders
|
7.1%
18/255 • Number of events 26 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
General disorders
General disorders and administration site conditions
|
1.6%
4/255 • Number of events 4 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Hepatobiliary disorders
Hepatobiliary disorders
|
1.2%
3/255 • Number of events 3 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Immune system disorders
Immune system disorders
|
0.39%
1/255 • Number of events 1 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Infections and infestations
Infections and infestations
|
1.2%
3/255 • Number of events 4 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Injury, poisoning and procedural complications
Injury, poisoning and procedural complications
|
0.39%
1/255 • Number of events 1 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Investigations
Investigations
|
0.39%
1/255 • Number of events 1 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Metabolism and nutrition disorders
Metabolism and nutrition disorders
|
1.6%
4/255 • Number of events 5 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Nervous system disorders
Nervous system disorders
|
0.39%
1/255 • Number of events 1 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Renal and urinary disorders
Renal and urinary disorders
|
1.2%
3/255 • Number of events 4 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory, thoracic and mediastinal disorders
|
0.78%
2/255 • Number of events 2 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Vascular disorders
Vascular disorders
|
0.78%
2/255 • Number of events 2 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
Other adverse events
| Measure |
Non Interventional
n=255 participants at risk
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study
|
|---|---|
|
Blood and lymphatic system disorders
Blood and lymphatic system disorders
|
9.0%
23/255 • Number of events 24 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Cardiac disorders
Cardiac disorders
|
0.39%
1/255 • Number of events 1 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Gastrointestinal disorders
Gastrointestinal disorders
|
14.5%
37/255 • Number of events 51 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
General disorders
General disorders and administration site conditions
|
9.8%
25/255 • Number of events 28 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Hepatobiliary disorders
Hepatobiliary disorders
|
0.78%
2/255 • Number of events 2 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Immune system disorders
Immune system disorders
|
0.39%
1/255 • Number of events 1 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Infections and infestations
Infections and infestations
|
0.39%
1/255 • Number of events 1 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Injury, poisoning and procedural complications
Injury, poisoning and procedural complications
|
0.39%
1/255 • Number of events 1 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Investigations
Investigations
|
0.78%
2/255 • Number of events 2 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Metabolism and nutrition disorders
Metabolism and nutrition disorders
|
1.2%
3/255 • Number of events 3 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal and connective tissue disorders
|
0.78%
2/255 • Number of events 2 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Nervous system disorders
Nervous system disorders
|
16.5%
42/255 • Number of events 44 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Renal and urinary disorders
Renal and urinary disorder
|
0.39%
1/255 • Number of events 1 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory, thoracic and mediastinal
|
2.4%
6/255 • Number of events 6 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders
|
5.1%
13/255 • Number of events 15 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
|
Vascular disorders
Vascular disorders
|
1.6%
4/255 • Number of events 4 • Time from treatment initiation (for mCRC) up to 31 December 2020
Since this is a retrospective study only relevant adverse events (AEs) have been collected. Definition of relevant AE: AE leading to first-line treatment switch, dose adaptation or discontinuation, or leading to death. Relevant AEs were assessed by System Organ Class (SOC).
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place